Caterina P. Profaci

Caterina P. Profaci

Auto-generated profile, based on publicly available information

Caterina P. Profaci

Departments of Pharmacology and Neurosciences, University of California, San Diego, La Jolla, CA, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CPCaterina P. Profaci
Caterina P. Profaci
RMRoeben N. Munji
Roeben N. Munji
RPRobert S. Pulido
Robert S. Pulido
RDRichard Daneman
Richard Daneman
The blood vessels vascularizing the central nervous system exhibit a series of distinct properties that tightly control the movement of ions, molecules, and cells between the blood and the parenchyma. This “blood–brain barrier” is initiated during angiogenesis via signals from the surrounding neural environment, and its integrity remains vital for homeostasis and neural protection throughout life. Blood–brain barrier dysfunction contributes to pathology in a range of neurological conditions including multiple sclerosis, stroke, and epilepsy, and has also been implicated in neurodegenerative diseases such as Alzheimer’s disease. This review will discuss current knowledge and key unanswered questions regarding the blood–brain barrier in health and disease.

22 December 2013 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
UKUsman A Khan
Usman A Khan
LLLi Liu
Li Liu
FPFrank A Provenzano
Frank A Provenzano
DBDiego E Berman
Diego E Berman
CPCaterina P Profaci
Caterina P Profaci
SSScott A Small
Scott A Small

18 February 2022 in Science
Verified
Journal Article
Closed access
MMMaud Martin
Maud Martin
SVSimon Vermeiren
Simon Vermeiren
NBNaguissa Bostaille
Naguissa Bostaille
MEMarie Eubelen
Marie Eubelen
DSDaniel Spitzer
Daniel Spitzer
BVBenoit Vanhollebeke
Benoit Vanhollebeke
The blood-brain barrier (BBB) protects the central nervous system (CNS) from harmful blood-borne factors. Although BBB dysfunction is a hallmark of several neurological disorders, therapies to restore BBB function are lacking. An attractive strategy is to repurpose developmental BBB regulators, such as Wnt7a, into BBB-protective agents. However, safe therapeutic use of Wnt ligands is complicated by their pleiotropic Frizzled signaling activities. Taking advantage of the Wnt7a/b-specific Gpr124/Reck co-receptor complex, we genetically engineered Wnt7a ligands into BBB-specific Wnt activators. In a “hit-and-run” adeno-associated virus–assisted CNS gene delivery setting, these new Gpr124/Reck-specific agonists protected BBB function, thereby mitigating glioblastoma expansion and ischemic stroke infarction. This work reveals that the signaling specificity of Wnt ligands is adjustable and defines a modality to treat CNS disorders by normalizing the BBB.

6 June 2011 in Journal of Neurochemistry
Verified
Journal Article
Open access
PDF file
JNJoseph H. Neale
Joseph H. Neale
RORafal T. Olszewski
Rafal T. Olszewski
DZDaiying Zuo
Daiying Zuo
KJKarolina J. Janczura
Karolina J. Janczura
CPCaterina P. Profaci
Caterina P. Profaci
TBTomasz Bzdega
Tomasz Bzdega
J. Neurochem. (2011) 118, 490–498. A substantial body of data was reported between 1984 and 2000 demonstrating that the neuropeptide N‐acetylaspartylglutamate (NAAG) not only functions as a neurotransmitter but also is the third most prevalent transmitter in the mammalian nervous system behind glutamate and GABA. By 2005, this conclusion was validated further through a series of studies in vivo and in vitro. The primary enzyme responsible for the inactivation of NAAG following its synaptic release had been cloned, characterized and knocked out. Potent inhibitors of this enzyme were developed and their efficacy has been extensively studied in a series of animal models of clinical conditions, including stroke, peripheral neuropathy, traumatic brain injury, inflammatory and neuropathic pain, cocaine addiction, and schizophrenia. Considerable progress also has been made in defining further the mechanism of action of these peptidase inhibitors in elevating synaptic levels of NAAG with the consequent inhibition of transmitter release via the activation of pre‐synaptic metabotropic glutamate receptor 3 by this peptide. Very recent discoveries include identification of two different nervous system enzymes that mediate the synthesis of NAAG from N‐acetylaspartate and glutamate and the finding that one of these enzymes also mediates the synthesis of a second member of the NAAG family of neuropeptides, N‐acetylaspartylglutamylglutamate.

1 May 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YMYinghua Ma
Yinghua Ma
DSDavid Sannino
David Sannino
JLJennifer Linden
Jennifer Linden
SHSylvia Haigh
Sylvia Haigh
BZBaohua Zhao
Baohua Zhao
TVTimothy Vartanian
Timothy Vartanian
Multiple sclerosis (MS) is a complex disease of the CNS thought to require an environmental trigger. Gut dysbiosis is common in MS, but specific causative species are unknown. To address this knowledge gap, we used sensitive and quantitative PCR detection to show that people with MS were more likely to harbor and show a greater abundance of epsilon toxin–producing (ETX-producing) strains of C. perfringens within their gut microbiomes compared with individuals who are healthy controls (HCs). Isolates derived from patients with MS produced functional ETX and had a genetic architecture typical of highly conjugative plasmids. In the active immunization model of experimental autoimmune encephalomyelitis (EAE), where pertussis toxin (PTX) is used to overcome CNS immune privilege, ETX can substitute for PTX. In contrast to PTX-induced EAE, where inflammatory demyelination is largely restricted to the spinal cord, ETX-induced EAE caused demyelination in the corpus callosum, thalamus, cerebellum, brainstem, and spinal cord, more akin to the neuroanatomical lesion distribution seen in MS. CNS endothelial cell transcriptional profiles revealed ETX-induced genes that are known to play a role in overcoming CNS immune privilege. Together, these findings suggest that ETX-producing C. perfringens strains are biologically plausible pathogens in MS that trigger inflammatory demyelination in the context of circulating myelin autoreactive lymphocytes.

31 July 2012 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
ROR T Olszewski
R T Olszewski
KJK J Janczura
K J Janczura
SBS R Ball
S R Ball
JMJ C Madore
J C Madore
KLK M Lavin
K M Lavin
JNJoseph H. Neale
Joseph H. Neale
The most widely validated animal models of the positive, negative and cognitive symptoms of schizophrenia involve administration of d-amphetamine or the open channel NMDA receptor blockers, dizocilpine (MK-801), phencyclidine (PCP) and ketamine. The drug ZJ43 potently inhibits glutamate carboxypeptidase II (GCPII), an enzyme that inactivates the peptide transmitter N-acetylaspartylglutamate (NAAG) and reduces positive and negative behaviors induced by PCP in several of these models. NAAG is an agonist at the metabotropic glutamate receptor 3 (mGluR3). Polymorphisms in this receptor have been associated with expression of schizophrenia. This study aimed to determine whether two different NAAG peptidase inhibitors are effective in dopamine models, whether their efficacy was eliminated in GCPII knockout mice and whether the efficacy of these inhibitors extended to MK-801-induced cognitive deficits as assessed using the novel object recognition test. ZJ43 blocked motor activation when given before or after d-amphetamine treatment. (R,S)-2-phosphono-methylpentanedioic acid (2-PMPA), another potent NAAG peptidase inhibitor, also reduced motor activation induced by PCP or d-amphetamine. 2-PMPA was not effective in GCPII knockout mice. ZJ43 and 2-PMPA also blocked MK-801-induced deficits in novel object recognition when given before, but not after, the acquisition trial. The group II mGluR antagonist LY341495 blocked the effects of NAAG peptidase inhibition in these studies. 2-PMPA was more potent than ZJ43 in a test of NAAG peptidase inhibition in vivo. By bridging the dopamine and glutamate theories of schizophrenia with two structurally different NAAG peptidase inhibitors and demonstrating their efficacy in blocking MK-801-induced memory deficits, these data advance the concept that NAAG peptidase inhibition represents a potentially novel antipsychotic therapy.